Bringing the future into medtech with our device:
VisU Pro by NoviPel is our revolutionising biofeedback solution for clinical assessment and diagnosis of female urinary incontinence (UI) supporting the first line treatment: pelvic floor muscle training (PFMT)
NoviPel aims to be a leading medtech developer battling incontinence – a growing and costly problem.
It is our vision to develop a new generation of devices that meets the high demands of the professionals, and also caters the expectations from the patients.
We bring the future into medical product development for clinical assessment, diagnosis and treatment of incontinence.
We optimise current methods and solutions to improve the quality of life of those affected by incontinence.
User Experience is central to all aspects of our product development. We want to create products that are not only functional but exceed expectations and delight our customers.
We align ourselves, throughout all our product development processes with health care practitioners, patients and regulatory authorities.
CEO & Founder
Android Lead Programmer
Brand- & Marketing Manager
We are more than our device
We want to be more than just our device. Our solution is an end to a bigger mean; creating a platform of research based knowledge on how to improve treatment of incontinence through pelvic floor muscle training (PFMT).
We want to inform women about urinary incontinence and help break the taboo so we can raise the current numbers of women seeking professional help, and making the number of women with urinary incontinence (UI) shrink profoundly.
We encourage women suffering from involuntary leakage of urine, no matter the severity of it, to take control and seek medical advice!
NoviPel is a Danish medtech company of healthcare professionals, designers, and engineers disrupting the market for female urinary incontinence (UI) with our biofeedback device: VisU Pro.
Get in touch
We are looking for investors interested in ja company battling a growing and costly problem: Urinary Incontinence.